Check out our most popular compounded medications! Get Started
Licensed to fill prescriptions for patients in RI, MA, CT, NJ, NH, FL, ME and PA. New York patients are served on a limited basis while nonresident registration is pending.
Prepared to a prescriber's order for one patient. Not FDA-approved.
This is a compounded capsule containing zonisamide, prepared to a prescriber's order for one patient. Compounded preparations are not FDA-approved.
These listings cover every salt or ester form of each drug in the FDA National Drug Code Directory.
FDA-approved products containing zonisamide are listed in capsule and suspension forms.
This is a solid, nonaqueous dose form. Under USP <795>, nonaqueous preparations carry longer default beyond-use dates than water-containing ones. The date printed on the label is the one to follow.
Zonisamide is a sulfonamide-type antiseizure medicine taken by mouth that a pharmacy may compound, including as an oral suspension, when a prescriber orders it.
Zonisamide is an antiseizure drug chemically classified as a sulfonamide and unrelated to other antiseizure agents. Its exact mechanism is unknown; laboratory studies suggest it blocks sodium channels and T-type calcium channels, which steadies overactive nerve cells, and it is also a weak carbonic anhydrase inhibitor. Manufactured products are Zonegran capsules and generic zonisamide capsules, indicated as adjunctive therapy for partial seizures in adults with epilepsy, and Zonisade oral suspension, indicated as adjunctive therapy for partial-onset seizures in adults and pediatric patients 16 years and older. A published compounding study describes zonisamide oral suspensions prepared for children at a time when no liquid was commercially available. A prescriber might order zonisamide compounded in a strength or vehicle that is not manufactured. Compounded preparations are not FDA-approved and require a prescription.
Zonisamide labels carry no boxed warning. Do not take it if you are allergic to sulfonamides (sulfa drugs) or zonisamide; serious reactions, including severe skin reactions, liver failure, blood disorders and a multi-organ reaction called DRESS, have been fatal. Other label warnings include decreased sweating and overheating, especially in children; sudden vision changes or eye pain; suicidal thoughts; metabolic acidosis, which can lead to kidney stones and bone problems; drowsiness and trouble thinking; and high ammonia levels. Do not stop suddenly, because seizures can worsen. Other carbonic anhydrase inhibitors such as topiramate or acetazolamide add to acidosis and kidney stone risk; valproic acid and topiramate add to ammonia risk; alcohol and sedatives add to drowsiness; and phenytoin and carbamazepine lower its levels. The label says it may harm an unborn baby and advises birth control for women who can become pregnant. LactMed says alternative drugs are preferred during breastfeeding. Talk to your prescriber or pharmacist about side effects.
Zonisamide is a 1,2-benzisoxazole sulfonamide that blocks voltage-dependent sodium and T-type calcium channels and weakly inhibits carbonic anhydrase (Zonegran label; StatPearls). Per the Zonegran label, peak plasma levels occur at 2 to 6 hours (4 to 6 hours with food, without change in bioavailability); it is about 40 percent bound to plasma proteins and binds extensively to erythrocytes, reaching about eight-fold higher levels in red cells than in plasma; it is acetylated and reduced by CYP3A4 to SMAP; and the plasma half-life is about 63 hours, so steady state takes about 14 days. Enzyme-inducing antiseizure drugs increase clearance. Labeled indications: adjunctive therapy for partial seizures in adults (Zonegran capsules, NDA; generic capsules, ANDA) and partial-onset seizures in patients 16 years and older (Zonisade oral suspension, NDA). StatPearls describes study of neuropathic pain, Parkinson disease motor symptoms and essential tremor; these are not FDA-approved indications. Nahata (IJPC 2016) reported compounded zonisamide suspensions stable for 91 days for pediatric use. Check serum bicarbonate, BUN and creatinine, and CBC at baseline and periodically (StatPearls). Zonisamide is not a controlled substance on these labels. Dosing is per prescriber.
Swallow each capsule whole with a glass of water, unless your label says otherwise. Do not crush, chew or open the capsule unless your pharmacist tells you it is safe to do so. Take it at the times shown on your prescription label. If you miss a dose or are unsure how to take it, call the pharmacy.
Capsules are nonaqueous, so under USP <795> they usually carry a beyond-use date of up to 180 days when no other stability data apply. Keep the vial tightly closed at room temperature, away from heat, moisture and direct light, and out of reach of children. Discard any capsules left after the beyond-use date on the label.
This formulation is compounded by Bayview Pharmacy on a prescriber's order for an individual patient. It is not an FDA-approved drug product, and the FDA has not evaluated it for safety, effectiveness, or manufacturing quality.
A valid prescription is required. Availability depends on Bayview's licensure in your state. This page is general information, not medical advice. Discuss your situation with a licensed healthcare provider.
Search by NCPDP 4106882, or by name and ZIP: Bayview Pharmacy, Warwick, RI 02886. Select it as the destination pharmacy and save it as a favorite. Click any value to copy it.
Compounded preparations have no NDC, so this formula will not appear in your EHR's drug search. Use your system's compound, non-formulary, or free-text prescription entry and name the preparation exactly as written in step 3. If your EHR forces you to pick a listed drug, pick the closest entry for the active ingredient and put the full formula in the prescription body (the Sig or directions field), not in Notes to Pharmacy.
Compounded preparations have no NDC and will not appear in your drug search. For EPCS to validate, select a drug entry your EHR recognizes as controlled, usually the bulk powder entry for the active ingredient (for example Ketamine (bulk) powder, not a branded product), then put the full formula from step 3 in the prescription body. A free-text entry that does not validate as controlled will be rejected by your EPCS module.
Quantity and directions are starting points for this dose form, not treatment recommendations. Dosing remains the prescriber's responsibility.
Transmit from your EHR. For this non-controlled preparation we also accept fax to (401) 284-4506 and phoned orders at (401) 284-4505. Order forms are on the formulation pages and in the prescriber portal.
Transmit with two-factor authentication through your EPCS-enabled EHR. No order form is offered for this preparation; e-prescribing guides for our controlled preparations are on the formulation pages.
Licensed to dispense in RI, MA, CT, NJ, NH, FL, ME, and PA; New York is served on a limited basis while nonresident registration is pending. Compounded preparations are not FDA-approved. A valid prescription is required. Full guide, including steps by EHR: How to e-prescribe to Bayview. Questions about this formula: call (401) 284-4505.
Take 1 capsule by mouth
